Semaglutide vs Metformin: How They Compare for Weight Loss & Blood Sugar

For weight loss, semaglutide vs metformin is not a close contest. Metformin is not FDA-approved for weight loss, and in the Diabetes Prevention Program it lowered body weight by about 2% on average (Diabetes Care, 2012). Semaglutide is approved for weight management as Wegovy, and in STEP 1 adults lost 14.9% of their body weight over 68 weeks.

For blood sugar in type 2 diabetes, both work. Metformin is the inexpensive, long-established starting point. Semaglutide lowers A1C by a similar amount in label trials and adds proven heart and kidney benefits for the people who need them.

You may not have to choose. Most semaglutide diabetes trials enrolled people already taking metformin.

Each drug lowers blood sugar by a different route.

Metformin: a biguanide

Metformin is a biguanide, not a GLP-1. On its FDA label, it reduces the glucose your liver releases, lowers glucose absorption from the gut and helps muscle and other tissues respond to insulin. It does not push the pancreas to release more insulin (metformin prescribing information).

You take it with meals, once or twice a day. The immediate-release label runs from 500 mg twice a day or 850 mg once a day up to 2,550 mg a day.

Semaglutide: a GLP-1 receptor agonist

Semaglutide copies GLP-1, a hormone your gut releases after a meal. It prompts the pancreas to release insulin when blood sugar is high, lowers glucagon, slows stomach emptying and turns down appetite signals in the brain. That appetite effect drives most of its weight loss.

One molecule is sold under three brand names. Ozempic is a weekly injection for type 2 diabetes. Rybelsus is a daily tablet for diabetes. Wegovy is approved for weight management, as a weekly injection or a daily tablet. Our breakdown of Ozempic vs Wegovy vs Rybelsus covers the brand split.

No trial has compared the two drugs head to head for weight. Figures below come from separate trials in different populations and show a direction, not an exact difference.

Metformin

In the Diabetes Prevention Program, 3,234 adults with prediabetes took metformin 850 mg twice a day, placebo or an intensive lifestyle program. Over an average of 2.8 years, the metformin group lost 2.1 kg, against 0.1 kg on placebo and 5.6 kg with the lifestyle program (NEJM, 2002).

On metformin's own label, adults with type 2 diabetes lost 1.4 lb over 29 weeks, against 2.4 lb on placebo. The ADA's 2026 Standards of Care sum it up: weight loss, but under 5% of body weight.

Semaglutide

In STEP 1, adults without diabetes on Wegovy 2.4 mg a week lost 14.9% of body weight at 68 weeks, against 2.4% on placebo. In STEP 2, adults with type 2 diabetes lost 9.6% against 3.4%. The daily 25 mg Wegovy tablet produced 13.6% at 64 weeks (Wegovy prescribing information).

For adults with diabetes and overweight or obesity, the ADA now names semaglutide or tirzepatide as the preferred weight-loss medication (ADA Standards of Care, Section 8). Metformin is not on that list and is not FDA-approved for weight loss at any dose.

Scroll the table sideways to see both columns →

Both lower A1C, the three-month average of blood sugar, by a similar amount when used alone in their label trials. Metformin lowered A1C by 1.4 points at 29 weeks, against a 0.4-point rise on placebo. Ozempic lowered it by 1.4 to 1.6 points at 30 weeks, against 0.1 on placebo, and cut weight by 3.8 to 4.7 kg as well.

Separate trials do not settle which drug is stronger. The ADA is clearer: semaglutide sits among the medications with the highest glucose-lowering effect, and adding a GLP-1 to metformin usually lowers A1C by a further 1 to 2 points or more (ADA Standards of Care, Section 9). Our article on semaglutide and A1C covers how clinicians track it.

Ozempic also protects beyond glucose. Its FDA indications include cutting the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes and heart disease, and slowing kidney decline in chronic kidney disease. Metformin's label says no clinical study has shown conclusive evidence that it lowers that kind of heart and blood vessel risk.

Rybelsus vs metformin: two pills

If you want a tablet either way, Rybelsus vs metformin is the fair comparison. In PIONEER 1, Rybelsus lowered A1C by 1.2 to 1.4 points at 26 weeks, against 0.3 on placebo, with 2.3 to 3.7 kg of weight loss, and it now carries a cardiovascular indication.

Routine is where they differ. You take Rybelsus once a day on an empty stomach with no more than 4 ounces of water, then wait 30 minutes before food, drinks or other pills. Metformin goes with meals. Lower doses of oral semaglutide are now also sold as Ozempic tablets, which the label says are not interchangeable with Rybelsus milligram for milligram (Rybelsus prescribing information).

Both drugs mostly affect the stomach, in different ways and with different rare risks.

Metformin

Diarrhea is the main complaint. In the immediate-release label trial, 53% of people on metformin had diarrhea, against 12% on placebo, and 6% stopped the drug because of it. Nausea or vomiting affected 26%. Extended-release metformin was far gentler in its own trial, with diarrhea in 10%, and taking it with meals and raising the dose slowly also helps.

Its boxed warning is lactic acidosis, a dangerous acid buildup the ADA calls very rare. Kidney problems, heavy drinking, contrast scans and serious illness raise the risk, so metformin is not used below an eGFR of 30. Long-term use can lower vitamin B12, so periodic checks are recommended.

Semaglutide

On Ozempic 1 mg, 20.3% of people reported nausea, against 6.1% on placebo, mostly during dose increases. On Wegovy 2.4 mg, the weight-loss dose, nausea reached 44% against 16%. Semaglutide carries a boxed warning for thyroid C-cell tumors seen in rodents, and it is not used with a personal or family history of medullary thyroid carcinoma or MEN 2.

Neither drug usually causes low blood sugar on its own. Both labels note the risk rises with insulin or a sulfonylurea.

Taking both is common and well studied. Ozempic's diabetes trials enrolled people on metformin, 94% of them in one trial, and 76% of people in the SOUL trial of oral semaglutide were on metformin at the start. The Ozempic and Rybelsus labels report no clinically relevant interaction with metformin, so no dose change is needed.

Semaglutide prescribed for weight follows the same rule. The Wegovy label warns against other GLP-1 drugs, not metformin. It asks people with diabetes to check blood sugar before and during treatment, since lower weight and glucose can change the rest of the plan.

If you take metformin and are considering a semaglutide program, list it at intake and keep the doctor who manages your diabetes informed.

Metformin is one of the least expensive drugs in diabetes care. The ADA's 2026 tables put the pharmacy acquisition cost of a month of immediate-release metformin at $1 to $2.

Brand semaglutide sits on a different scale. The same ADA tables list Ozempic at a wholesale price of $1,197 for 30 days and Wegovy at $1,619. A federal program launched in February 2026 lists Ozempic and injectable Wegovy at an average of $350 a month and the Wegovy pill from $149, depending on dose (White House). Insurance coverage for weight loss varies widely.

Arbor's semaglutide weight program starts at $99 a month and stays there as your dose rises. It is compounded semaglutide, prepared by a licensed U.S. pharmacy, and it is not FDA-approved. Our semaglutide cost guide compares the brand options.

Arbor's semaglutide program is for weight management and does not replace a diabetes plan.

Metformin alone may fit when

• Blood sugar control in type 2 diabetes is the main goal and cost decides it
• Your doctor is using it to lower diabetes risk in prediabetes, as the ADA suggests for some high-risk adults
• Weight is not the main concern

Semaglutide may fit when

• Weight is the main goal and your BMI qualifies for weight-management treatment
• You have type 2 diabetes with overweight or obesity, where the ADA prefers semaglutide or tirzepatide
• You also have heart or kidney disease, where semaglutide carries proven benefits
• You already take metformin and want to add weight treatment

For how GLP-1s, insulin and metformin fit together, see our guide to GLP-1s, insulin and metformin.